This Article Full Text Full Text (PDF) All Versions of this Article: 35/7/1677    most recent 01.STR.0000131549.20581.bav1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LaMonte, M. P. Search for Related Content PubMed PubMed Citation Articles by LaMonte, M. P. Related Collections Thrombin Coagulation inhibitors Other anticoagulants Acute Cerebral Infarction Anticoagulants

(Stroke. 2004;35:1677.)
© 2004 American Heart Association, Inc.

Original Contributions

Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1)

A Randomized, Placebo-Controlled Safety Study

Marian P. LaMonte, MD, MSN; Marshall L. Nash, MD; David Z. Wang, DO; Andrew R. Woolfenden, MD; John Schultz, PhD; Marcie J. Hursting, PhD Philip M. Brown, MD, JD for the ARGIS-1 Investigators

From the University of Maryland School of Medicine (M.P.L.), Baltimore, Md; Dekalb Neurology Associates/DNA Research (M.L.N.), Decatur, Ga; OSF Stroke Network (D.Z.W.), Peoria, Ill; Vancouver General Hospital (A.R.W.), Vancouver, BC, Canada; University of Virginia (J.S.), Charlottesville, Va; Clinical Science Consulting (M.J.H.), Potomac, Md; Encysive Pharmaceuticals (P.M.B.), Houston, TX

Correspondence to Dr Marian P. LaMonte, University of Maryland School of Medicine, 22 South Greene St, Room N4W46, Baltimore, MD 21201-1595. E-mail mlamonte{at}umm.edu

Background and Purpose— Direct thrombin inhibitors, including argatroban, represent an anticoagulant class distinct from heparins. We investigated the safety of 2 levels of argatroban anticoagulation in acute ischemic stroke.

Methods— This multicenter, randomized, double-blinded, placebo-controlled study included 171 patients with acute (12 hours from onset) stroke and National Institutes of Health Stroke Scale (NIHSS) scores of 5 to 22. Patients received continuous intravenous argatroban (100 µg/kg bolus) at 3 µg/kg per minute (n=59) or 1 µg/kg per minute (n=58), respectively, adjusted to target activated partial thromboplastin times (aPTTs) 2.25x and 1.75x baseline or placebo (n=54) for 5 days. The primary outcome was symptomatic intracranial hemorrhage (ICH) at 30 days.

Results— Baseline characteristics including neurologic deficits (median NIHSS score 9) were comparable between groups. Argatroban at mean doses of 2.7 and 1.2 µg/kg per minute increased aPTTs significantly (P<0.001), with mean aPTTs at or near target values throughout infusion. Symptomatic ICH was not significantly different between groups (high-dose argatroban, 5.1%; low-dose argatroban, 3.4%; placebo, 0%; P0.18), with 3 events during argatroban infusion and 2 events 7 days after stopping infusion. No significant between-group differences occurred in asymptomatic ICH (7 events), major systemic hemorrhage (no event), or 90-day mortality (13.4% overall).

Conclusions— In this first North American randomized, double-blinded, placebo-controlled study of direct thrombin inhibition in acute ischemic stroke, argatroban at each dose evaluated significantly prolonged aPTTs without increasing ICH or major bleeding. These results suggest that argatroban provides safe anticoagulation in acute ischemic stroke, warranting future studies powered to evaluate its efficacy and more precisely estimate event rates.

Key Words: stroke, acute • thrombin, antagonists and inhibitors • randomized controlled trails • anticoagulent agents

This article has been cited by other articles:

				P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]

				A. M. Pancioli Combination Pharmacotherapy for Achievement and Maintenance of Vascular Patency Stroke, March 1, 2009; 40(3_suppl_1): S99 - S102. [Abstract] [Full Text] [PDF]

				S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]

				M. Paciaroni, G. Agnelli, S. Micheli, and V. Caso Response to Letter by Guedes and Ferro Stroke, May 1, 2008; 39(5): e83 - e83. [Full Text] [PDF]

				P. Khatri, L. R. Wechsler, and J. P. Broderick Intracranial Hemorrhage Associated With Revascularization Therapies Stroke, February 1, 2007; 38(2): 431 - 440. [Abstract] [Full Text] [PDF]

				R. M. Sugg, J. K. Pary, K. Uchino, S. Baraniuk, H. M. Shaltoni, N. R. Gonzales, R. Mikulik, Z. Garami, S. G. Shaw, D. E. Matherne, et al. Argatroban tPA Stroke Study: Study Design and Results in the First Treated Cohort. Arch Neurol, August 1, 2006; 63(8): 1057 - 1062. [Abstract] [Full Text] [PDF]

				M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]

				H. Adams, R. Adams, G. Del Zoppo, and L. B. Goldstein Guidelines for the Early Management of Patients With Ischemic Stroke: 2005 Guidelines Update A Scientific Statement From the Stroke Council of the American Heart Association/American Stroke Association Stroke, April 1, 2005; 36(4): 916 - 923. [Full Text] [PDF]